𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease

✍ Scribed by S. Din; C.J. Cochrane; C.L. Noble; J. Satsangi; I.D.R. Arnott

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
79 KB
Volume
14
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis

FIGURE 1. Disease progression. Kaplan-Meier analysis demonstrating disease progression over the follow-up period between the groups.

📜 SIMILAR VOLUMES

Endoscopic monitoring of infliximab ther
Endoscopic monitoring of infliximab therapy in Crohn's disease
✍ Clas-Göran af Björkesten; Urpo Nieminen; Ulla Turunen; Perttu E. Arkkila; Taina 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB 👁 1 views

## Background: So far, infliximab (ifx) therapy for the treatment of crohn's disease (cd) has generally been guided by clinical symptoms. data on treatment response as ascertained by endoscopy in ifx therapy are scarce. the aims of this study were to measure the endoscopic response rate during ifx

Changes of OPG and RANKL concentrations
Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy
✍ Pál Miheller; Györgyi Műzes; Károly Rácz; Anna Blázovits; Péter Lakatos; László 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Background: Osteoporosis is a well-known complication of crohn's disease (cd). osteoprotegerin (opg) concentration is elevated in patients with cd compared to healthy controls. long-term infliximab (ifx) maintenance therapy improves the patients' bone mineral density. the effect of ifx on bone m

Tolerance and efficacy of azathioprine i
Tolerance and efficacy of azathioprine in pediatric Crohn's disease
✍ Laura Riello; Cécile Talbotec; Hélène Garnier-Lengliné; Bénédicte Pigneur; Johan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Background: Thiopurines are considered first-line immunomodulators for the prevention of relapse in moderate to severe pediatric crohn's disease (cd). early introduction of thiopurines was shown in a pediatric trial to maintain steroid-free remission in 90% of patients for 18 months. in the pres